SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment
with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to
this study is planned as a separate protocol for patients who are willing and eligible to
participate.